Mangoceuticals, Inc. (NASDAQ: MGRX)

Sector: Healthcare Industry: Health Information Services CIK: 0001938046
Market Cap 4.01 Mn
P/B 0.26
P/E -0.20
P/S 8.59
ROIC (Qtr) -108.32
Div Yield % 0.00
Rev 1y % (Qtr) -36.83
Total Debt (Qtr) 112,167.00
Debt/Equity (Qtr) 0.01

About

Mangoceuticals, Inc., or MGRX, operates in the men's wellness telemedicine services and products industry. The company, founded in October 2021 and based in Texas, went public in March 2023, raising approximately $5 million in its initial public offering (IPO). Mangoceuticals specializes in connecting consumers to licensed healthcare professionals through its website for the provision of care via telehealth, a digital platform that allows customers to consult with healthcare professionals remotely and receive prescriptions for medications. Two...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 498223 provide 4.44x coverage of short-term debt 112167, demonstrating strong liquidity position and minimal refinancing risk.
  • Operating cash flow of (5.90M) provides exceptional 16.09x coverage of interest expenses (366748), showing strong debt service capability.
  • Operating cash flow of (5.90M) provides exceptional 6543.31x coverage of minority interest expenses (902), showing strong core operations.
  • Strong tangible asset base of 611483 provides 5.45x coverage of total debt 112167, indicating robust asset backing and low credit risk.
  • Free cash flow of (5.90M) provides exceptional 16.09x coverage of interest expense (366748), showing strong debt service ability.

Bear case

  • The company's operating cash flow of (5.90M) shows concerning coverage of stock compensation expenses of 12.33M, with a -0.48 ratio indicating potential earnings quality issues.
  • Operating earnings of (20.19M) show weak coverage of depreciation charges of 1.56M, with a -12.92 ratio indicating high capital intensity and potential reinvestment needs.
  • Free cash flow of (5.90M) represents just -10.49x of debt issuance 562500, suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Operating cash flow of (5.90M) barely covers operating expenses of 11.24M with a -0.53 ratio, suggesting thin operational efficiency margins and limited flexibility.
  • Operating cash flow of (5.90M) is outpaced by equity issuance of 5.25M (-1.12 ratio), indicating concerning reliance on equity markets for funding operations.

Peer comparison

Companies in the Health Information Services
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TEM Tempus AI, Inc. 45.63 Bn -223.83 41.29 1.34 Bn
2 GEHC GE HealthCare Technologies Inc. 38.75 Bn 19.85 2.19 10.28 Bn
3 VEEV Veeva Systems Inc 37.30 Bn 43.36 12.11 0.09 Bn
4 DOCS Doximity, Inc. 7.81 Bn 30.87 12.57 0.01 Bn
5 BTSG BrightSpring Health Services, Inc. 7.70 Bn 59.42 0.62 2.70 Bn
6 HQY Healthequity, Inc. 7.32 Bn 38.14 5.67 1.03 Bn
7 WAY Waystar Holding Corp. 5.00 Bn 44.97 4.81 1.25 Bn
8 PRVA Privia Health Group, Inc. 2.79 Bn 153.67 1.37 0.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.27 2.77
EV to Cash from Ops. EV/CFO -0.77 -10.86
EV to Debt EV to Debt 40.33 161.93
EV to EBIT EV/EBIT -0.22 -106.48
EV to EBITDA EV/EBITDA -0.25 4.22
EV to Free Cash Flow [EV/FCF] EV/FCF -0.77 7.46
EV to Market Cap EV to Market Cap 1.13 -14.93
EV to Revenue EV/Rev 9.69 1.76
Price to Book Value [P/B] P/B 0.26 10.57
Price to Earnings [P/E] P/E -0.20 147.14
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) -68.42 -8.65
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 5.00
Dividend per Basic Share Div per Share (Qtr) 0.00 0.04
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 4.57
Interest Coverage Int. cover (Qtr) 55.05 -584.72
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 -24.09
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 448.38 172.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -1.05
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -127.82 -17.73
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -100.56 39.85
EBIT Growth (1y) % EBIT 1y % (Qtr) -127.82 -38.83
EBT Growth (1y) % EBT 1y % (Qtr) -112.55 -4.52
EPS Growth (1y) % EPS 1y % (Qtr) 39.76 2.60
FCF Growth (1y) % FCF 1y % (Qtr) -2,330.15 -48.57
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -36.03 5.49
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.03 0.66
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.03
Cash Ratio Cash Ratio (Qtr) 0.62 1.87
Current Ratio Curr Ratio (Qtr) 0.74 3.27
Debt to Equity Ratio Debt/Equity (Qtr) 0.01 -0.43
Interest Cover Ratio Int Coverage (Qtr) 55.05 -584.72
Times Interest Earned Times Interest Earned (Qtr) 55.05 -584.72
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -3,989.30 -435.80
EBIT Margin % EBIT Margin % (Qtr) -4,323.88 -464.70
EBT Margin % EBT Margin % (Qtr) -4,245.33 -461.74
Gross Margin % Gross Margin % (Qtr) 60.60 44.03
Net Profit Margin % Net Margin % (Qtr) -4,308.30 -468.01